MétaCan
Menu
← Back to cohort
Record W4310112889 · doi:10.21203/rs.3.rs-2280588/v1

PSMA PET/CT Patterns of Recurrence After Mono-Brachytherapy in Men with Low and Intermediate Prostate Cancer and Subsequent Management

2022· preprint· en· W4310112889 on OpenAlexaff
G. Loos, James P Buteau, Justin Oh, Kendrick Koo, Sylvia van Dyk, Nathan Lawrentschuk, Declan G. Murphy, Michael S. Hofman, Scott Willimas, Sarat Chander

Bibliographic record

VenueResearch Square · 2022
Typepreprint
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsMedicineProstate cancerBrachytherapyBiochemical recurrenceAndrogen deprivation therapyProstateSalvage therapyUrologyNuclear medicineRadiologyCancerRadiation therapyInternal medicineChemotherapyProstatectomy

Abstract

fetched live from OpenAlex

Abstract Purpose Brachytherapy as monotherapy is a recommended treatment option for men with low to intermediate risk prostate cancer, achieving biochemical progression-free survival rates >95% at 5 years. Local recurrence is difficult to identify due to sensitivity of conventional imaging and post-brachytherapy artefacts. Biochemical recurrence (BCR) in this setting is often considered as systemic recurrence, treated with androgen-deprivation therapy (ADT) as primary salvage therapy. This study investigated PSMA PET/CT for recurrence after low-dose rate (LDR) and high-dose rate (HDR) brachytherapy as monotherapy in men with low or intermediate prostate cancer, as well as subsequent management when recurrence occurred only within the prostate. Methods We performed a retrospective single-centre analysis for patients who were treated with brachytherapy as monotherapy for prostate cancer from May 2002 to May 2021 to identify men who underwent [68Ga]Ga-PSMA-11 or [18F]DCFPyL PET/CT (PSMA PET/CT) for BCR. We report the findings on PSMA PET/CT, quantitative parameters, as well as the subsequent management of the patients. Results Forty patients were identified who underwent PSMA PET/CT (26 LDR and 14 HDR) to investigate a rising PSA at a median (IQR) of 7 years (3.0-10.8) after initial therapy. Median (IQR) PSA at time of PSMA PET/CT was 6.6 ng/mL (3.9 - 15.5). On PSMA PET/CT, 20/40 (50%) men had prostate-only recurrence, 5/40 (12.5%) had nodal recurrence, 2/40 (5%) had bone-only metastases, 10/40 (25%) had multiple sites of recurrence and 3/40 (7.5%) had no visible sites of recurrence. Of the 20 patients with prostate-only recurrence, 8/20 (40%) had recurrence in a high-dose radiation zone, such as within the brachytherapy seeds, versus 7/20 (35%) in an under-covered zone, such as seminal vesicles or prostate base. On PSMA PET/CT, recurrence within the prostate had median (IQR) SUVmax 10.4 (5.1-15.7) and volume 2.9 mL (2.0-11.2). Subsequent management of these patients with local recurrence included surveillance followed by ADT (9/20, 45%), salvage SBRT (3/20, 15%), salvage brachytherapy (2/20, 10%), salvage radical prostatectomy (1/20, 5%) and not treated/lost to follow-up (5/20, 25%). For those with surveillance followed by ADT, the mean time before introduction of ADT was 4.1 years (range 1 to 8 years). Conclusion In the setting of BCR following mono-brachytherapy, PSMA PET/CT effectively identified local recurrence occurring within the prostate, including within high-dose radiation zones. It may be safe to delay the introduction of ADT, though more research is required.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.384
Teacher spread0.351 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueResearch Square→Same topicProstate Cancer Treatment and Research→French-language works237,207→